Stephen Paul Collingwood

This inventor holds 28 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 16 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Novartis Ag, Respivert Limited, Isis Pharmaceuticals, Inc.. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen Paul Collingwood. Retrieved from https://idiyas.com/inventor/stephen-paul-collingwood

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 8)

% Patents Active = 50.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 16 (Patent Applications = 7)

Average Co-Inventor Count = 5.1

ph-index = 6

Forward Citations = 171(Granted Patents)

Location History:

Crawley, GB (2000 - 2003)
Maidenbower, Crawley, West Sussex, GB (2008)
West Sussex, GB (2011 - 2012)
Horsham, GB (2003 - 2017)
Haywards Heath, GB (2014 - 2021)
High Wycombe, GB (2020 - 2021)

Company Filing History:

Isis Pharmaceuticals, Inc.

Modern Biosciences Limited

patents

6. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2024

Loading Chart...

Areas of Expertise:

N-acyl Compounds

Indole Derivatives

Bicyclic Heterocycles

Protein Kinase Inhibitors

Epithelial Sodium Channel

Pyrazine Derivatives

Muscarinic Receptor Antagonists

PDE 5 Inhibitors

Oligonucleotide Analogues

Quinuclidine Derivatives

Inflammatory Conditions

Fibrotic Diseases

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12162836 - N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use (2024-12-10),

2. 11208381 - Indole derivatives and their use as protein kinase inhibitors (2021-12-28),

3. 11046672 - Indolinones compounds and their use in the treatment of fibrotic diseases (2021-06-29),

4. 10669235 - Indole derivatives and their use as protein kinase inhibitors (2020-06-02),

5. 9751876 - Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension (2017-09-05),

6. 9643983 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2017-05-09),

7. 9139586 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2015-09-22),

8. 9073921 - Salt forms of bicyclic heterocyclic derivatives (2015-07-07),

9. 9034879 - Heterocyclic compounds for the treatment of CF (2015-05-19),

10. 8883819 - Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension (2014-11-11),

11. 8697687 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2014-04-15),

12. 8664228 - 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases (2014-03-04),

13. 8318935 - Organic compounds 75074 (2012-11-27),

14. 8236808 - Pyrazine derivatives as ENAC blockers (2012-08-07),

15. 8168654 - Quinuclidine derivatives binding to mucarinic M3 receptors (2012-05-01),

Title: The Innovative Contributions of Stephen Paul Collingwood

Introduction

Stephen Paul Collingwood, a distinguished inventor based in Horsham, GB, has made significant strides in the field of medicinal chemistry. With a remarkable portfolio of 26 patents, his work encompasses innovations that target critical health challenges, especially in the realm of fibrotic diseases.

Latest Patents

Among his latest inventions are two noteworthy patents focusing on indole derivatives and indolinones. The first, titled "Indole derivatives and their use as protein kinase inhibitors," relates to a specific compound formula designed to combat fibrotic diseases like idiopathic pulmonary fibrosis. This invention not only includes the compound but also highlights compositions and applications in therapeutic treatments. The second patent, "Indolinones compounds and their use in the treatment of fibrotic diseases," follows a similar theme, detailing a unique compound formula aimed at treating interstitial lung diseases, particularly idiopathic pulmonary fibrosis. These patents reflect Collingwood's commitment to advancing medical treatments and improving patient outcomes.

Career Highlights

Stephen Paul Collingwood has garnered experience in leading pharmaceutical companies, including Novartis AG and Respivert Limited. His tenure at these organizations has equipped him with unique insights into drug development and innovation, solidifying his status as a reliable inventor in the industry.

Collaborations

Throughout his career, Collingwood has collaborated with influential colleagues, such as Gurdip Bhalay and Catherine Howsham. These partnerships have undoubtedly fostered an environment of creativity and innovation, allowing for the sharing of knowledge and expertise in their respective fields.

Conclusion

In conclusion, Stephen Paul Collingwood stands out as a prominent figure in the realm of medicinal innovation. His extensive patent portfolio highlights his dedication to addressing pressing health concerns and advancing the field of pharmacology. As he continues to develop novel compounds and treatment methods, Collingwood's contributions will likely impact countless lives in the years to come.

Profile summary based on public USPTO records.